Bevacizumab and subtype-adapted chemotherapy backbone in neuroendocrine tumors

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 976-977

  Hadoux, Julien ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; DRUG EFFICACY; HUMAN; LETTER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; NEUROENDOCRINE TUMORS;

EID: 84875739360     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.0351     Document Type: Letter

References (11)

1. Chan JA, Stuart K, Earle CC, et al: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963-2968, 2012.
2. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 26:3063-3072, 2008.
3. Ducreux M, Seitz J-F, Smith D, et al: Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of patients with metastatic well-differentiated duodeno-pancreatic endocrine tumors (BETTER study). J Clin Oncol 30:247s, 2012 (abstr 4036).
4. Mitry E, Walter T, Baudin E, et al: Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study). J Clin Oncol 30:256s, 2012 (abstr 4071).
5. Durante C, Boukheris H, Dromain C, et al: Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16:585-597, 2009.
6. Scoazec J-Y: Angiogenesis in neuroendocrine tumors: Therapeutic applications. Neuroendocrinology 97:45-56, 2013.
7. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006. (Pubitemid 46630459)
8. Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986-2991, 2007. (Pubitemid 46849574)
9. Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268-275, 2011.
10. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992.
11. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897-4904, 2005. (Pubitemid 46223995)